Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial

Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial

Source: 
BioSpace
snippet: 

Alnilam – the bright center star in the middle of Orion’s belt – has navigated its namesake Alnylam to positive results in their ILLUMINATE-B Phase III clinical trial evaluating RNAi therapeutic, lumasiran, in young children with Primary hyperoxaluria Type 1 (PH1).